2. Search Result
Search Result
Isoforms Recommended: EZH1
Results for "

EZH1

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15555
    EPZ005687
    5 Publications Verification

    		 Histone Methyltransferase Cancer
    EPZ005687 is a potent and selective inhibitor of EZH2 with Ki of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.
    EPZ005687
  • HY-RS04616
    EZH1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    EZH1 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    EZH1 Human Pre-designed siRNA Set A
    EZH1 Human Pre-designed siRNA Set A
  • HY-RS04618
    Ezh1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Ezh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ezh1 Rat Pre-designed siRNA Set A
    Ezh1 Rat Pre-designed siRNA Set A
  • HY-122595
    EZH2-IN-1

    		Histone Methyltransferase Cancer
    EZH2-IN-1 (compound 3) is a selective and SAM-competitive EZH2 and EZH1 inhibitor with an IC50s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research [1].
    <em>EZH</em>2-IN-<em>1</em>
  • HY-145602
    Tulmimetostat

    CPI-0209

    		 Histone Methyltransferase Cancer
    Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies [1] .
    Tulmimetostat
  • HY-13803
    Tazemetostat
    Maximum Cited Publications
    51 Publications Verification

    EPZ-6438; E-7438

    		 Histone Methyltransferase Apoptosis Cancer
    Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells [1].
    Tazemetostat
  • HY-109108
    Valemetostat
    1 Publications Verification

    DS-3201

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma [1] .
    Valemetostat
  • HY-109108A
    Valemetostat tosylate
    1 Publications Verification

    DS-3201 tosylate

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma [1] .
    Valemetostat tosylate
  • HY-144881
    (S)-HH2853

    		Histone Methyltransferase Inflammation/Immunology Cancer
    (S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases [1].
    (S)-HH2853
  • HY-P2266
    SAH-EZH2

    		Histone Methyltransferase Cancer
    SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 [1].
    SAH-<em>EZH</em>2
  • HY-148458
    EZH2-IN-14

    		Histone Methyltransferase Cancer
    EZH2-IN-14 is a selective EZH2 (Histone Methyltransferase) inhibitor with an IC50 of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 [1].
    <em>EZH</em>2-IN-14

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: